[*]J.D. Candidate, May, 1999, Note Editor, MTTLR

[1]Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No 98-417, 98 Stat. 1585. The DPC-PTR Act is also referred to as the Waxman-Hatch exemption.

[2] U.S.C. § 271(e)(1) (emphasis added).

[3]Eli Lilly & Co. v. Medtronic, Inc., 696 F.Supp. 1033 (E.D. Pa. 1988), rev'd 872 F.2d (Fed. Cir. 1989), aff'd 496 U.S. 661 (1990).

[4]Id. at 672.

[5]Abtox, Inc., v. Exitron Corp., 122 F.3d 1019 (Fed. Cir. 1997).

[6]See Id. at 1028.

[7]Id. at 1029.

[8]Id. at 1029, quoting Eli Lilly 496 U.S. at 673-74.

[9]Medtronic, Inc., v. Lohr, -- U.S. --, 116 S.Ct. 2240 (1996).

[10]Abtox , 122 F.3d at 1029.

[11]See Scripps Clinic & Research Foundation v. Genentech Inc., 666 F.Supp 1379 (N.D. Calif. 1987).

[12]See Scripps Clinic & Research foundation, Inc. v. Baxter Travenol Laboratories, Inc. , 7 USPQ2d 1562 (D. Del. 1988) (Direct questions of Baxter's use of the product for gathering data beyond the requirements of the FDA were not raised.).

[13]Intermedics Inc. v. Ventritex Inc., 775 F.Supp 1269 (N.D. Calif. 1991), aff'd, 991 F.2d 808 (Fed. Cir. 1993)(unpublished).

[14]Id. at 1277.

[15]See Id. at 1277.

[16]Id. at 1278.

[17]Telectronics Pacing Systems, Inc. v. Ventritex, Inc., 982 F.2d 1520 (Fed. Cir. 1992).

[18]NeoRX Corp. v. Immunomedics, Inc., 877 F.Supp 202 (D.N.J. 1994).

[19]Id. at 206.

[20]See Id. at 207-208